Latest From Immunomedics Inc.
Previewing the year to come, our journalists contacted more than 80 industry executives and experts for their views on what 2020 could hold for the biopharma sector. A series of articles based on these discussions were published by In Vivo’s sister publication Scrip. The following are highlights of the key issues that are top of mind for industry leaders this year, including digital tools, advanced therapies, the US election and manufacturing.
From the general to the particular: drug developers are increasingly tailoring therapies to individuals. Driven by important advances in understanding biology as well as new tools to harness big data, industry participants expect significant progress in biopharma’s approach to the patient.
Executives and analysts predict trends spanning M&A, leadership diversity, curative gene therapy commercialization, biosimilars strategy and more. Expect technology innovation to continue to drive investment and deal making in biopharma.
Public Company Edition: The last biopharma initial public offering in the US was on 11 November, but follow-on and other offerings are generating hundreds of millions of dollars. Among RNA drug developers, Ionis issued more than $500m in new debt, while Arrowhead raised $266.8m.
- Large Molecule
- Radiopharmaceuticals, Contrast Agents
- Therapeutic Areas
- Immune Disorders
- North America
- Parent & Subsidiaries
- Immunomedics Inc.
- Senior Management
Usama Malik, CFO & CBO
Brendan Delaney, Chief Commercial Officer
Morris Rosenberg, CTO
- Contact Info
Phone: (973) 605-8200
300 The American Rd.
Morris Plains, NJ 07950
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.